AIM ImmunoTech Inc. Insider Trading

AIM

⊜ Compare

Last 12 months

Insiders bought 24K on the open market and sold nothing.

Net open-market

+24K

6 buys · 0 sales

Under a 10b5-1 plan

—

no sales

Insiders who bought / sold

1 / 0

executives and directors

Last open-market buy

Oct 2026

Oct 23, 2026

Get an email when AIM's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Oct 23	Thomas K Equels CEO & President	Bought	31,675	$0.16	5K	20%	Form 4
Oct 22	Thomas K Equels CEO & President	Bought	31,250	$0.16	5K	25%	Form 4
Sep 17	Thomas K Equels CEO & President	Bought	24,000	$0.21	5K	23%	Form 4
Sep 16	Thomas K Equels CEO & President	Bought	11,000	$0.21	2K	12%	Form 4
Sep 15	Thomas K Equels CEO & President	Bought	22,000	$0.22	5K	32%	Form 4
Sep 14	Thomas K Equels CEO & President	Bought	5,900	$0.22	1K	9.2%	Form 4
Jun 13, 2025	Thomas K Equels CEO & President	Bought	107	$7.70	$824	0.3%	Form 4
Jun 12, 2025	Thomas K Equels CEO & President	Bought	103	$8.70	$896	0.3%	Form 4
Apr 11, 2025	William M Mitchell Director	Bought	196,851	$0.03	6K	61%	Form 4
Apr 11, 2025	Thomas K Equels CEO & President	Bought	1,968,504	$0.03	59K	104%	Form 4
Apr 11, 2025	Ted D Kellner Director	Bought	1,968,504	$0.03	59K	112%	Form 4
Apr 4, 2025	Thomas K Equels CEO & President	Bought	41,000	$0.06	2K	2.2%	Form 4
Apr 4, 2025	Peter W Rodino III COO, Secretary, Gen. Counsel	Bought	500	$0.09	$45	0.1%	Form 4
Mar 5, 2025	Thomas K Equels CEO & President	Bought	50,000	$0.13	7K	2.8%	Form 4
Mar 4, 2025	Thomas K Equels CEO & President	Bought	44,000	$0.12	5K	2.5%	Form 4
Mar 4, 2025	Thomas K Equels CEO & President	Bought	83,334	$0.12	10K	5.0%	Form 4
Dec 19, 2024	William M Mitchell Director	SoldNo plan	4,580	$0.19	$870	3.7%	Form 4
Dec 18, 2024	Thomas K Equels CEO & President	Bought	22,727	$0.21	5K	1.4%	Form 4
Dec 2, 2024	Stewart Appelrouth Director	Bought 2 parts	11,112	$0.21 average	2K	3.2%	Form 4
Nov 21, 2024	Thomas K Equels CEO & President	Bought	20,000	$0.21	4K	1.2%	Form 4
Nov 20, 2024	Thomas K Equels CEO & President	Bought	85,000	$0.20	17K	5.5%	Form 4
Nov 20, 2024	Stewart Appelrouth Director	Bought	81,953	$0.19	16K	34%	Form 4
Nov 20, 2024	Thomas K Equels CEO & President	Bought	60,110	$0.18	11K	4.0%	Form 4

Oct 23
Thomas K Equels
CEO & President · bought 31,675 at $0.16
5K
20% of stake
Oct 22
Thomas K Equels
CEO & President · bought 31,250 at $0.16
5K
25% of stake
Sep 17
Thomas K Equels
CEO & President · bought 24,000 at $0.21
5K
23% of stake
Sep 16
Thomas K Equels
CEO & President · bought 11,000 at $0.21
2K
12% of stake
Sep 15
Thomas K Equels
CEO & President · bought 22,000 at $0.22
5K
32% of stake
Sep 14
Thomas K Equels
CEO & President · bought 5,900 at $0.22
1K
9.2% of stake
Jun 13, 2025
Thomas K Equels
CEO & President · bought 107 at $7.70
$824
0.3% of stake
Jun 12, 2025
Thomas K Equels
CEO & President · bought 103 at $8.70
$896
0.3% of stake
Apr 11, 2025
William M Mitchell
Director · bought 196,851 at $0.03
6K
61% of stake
Apr 11, 2025
Thomas K Equels
CEO & President · bought 1,968,504 at $0.03
59K
104% of stake
Apr 11, 2025
Ted D Kellner
Director · bought 1,968,504 at $0.03
59K
112% of stake
Apr 4, 2025
Thomas K Equels
CEO & President · bought 41,000 at $0.06
2K
2.2% of stake
Apr 4, 2025
Peter W Rodino III
COO, Secretary, Gen. Counsel · bought 500 at $0.09
$45
0.1% of stake
Mar 5, 2025
Thomas K Equels
CEO & President · bought 50,000 at $0.13
7K
2.8% of stake
Mar 4, 2025
Thomas K Equels
CEO & President · bought 44,000 at $0.12
5K
2.5% of stake
Mar 4, 2025
Thomas K Equels
CEO & President · bought 83,334 at $0.12
10K
5.0% of stake
Dec 19, 2024No plan
William M Mitchell
Director · sold 4,580 at $0.19
$870
3.7% of stake
Dec 18, 2024
Thomas K Equels
CEO & President · bought 22,727 at $0.21
5K
1.4% of stake
Dec 2, 2024
Stewart Appelrouth
Director · bought 11,112 at avg $0.21
2K
3.2% of stake
Nov 21, 2024
Thomas K Equels
CEO & President · bought 20,000 at $0.21
4K
1.2% of stake
Nov 20, 2024
Thomas K Equels
CEO & President · bought 85,000 at $0.20
17K
5.5% of stake
Nov 20, 2024
Stewart Appelrouth
Director · bought 81,953 at $0.19
16K
34% of stake
Nov 20, 2024
Thomas K Equels
CEO & President · bought 60,110 at $0.18
11K
4.0% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch AIM, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Biological Products, (No Diagnostic Substances) · Pick stocks to compare with AIM

CompareIntrinsic value

VIVSVivoSim Labs, Inc.

$0.15+8.71%10

INMBInmune Bio Inc.

$1.33+0.76%10

SNTISenti Biosciences Inc.

$0.18-0.79%0

ATYRAtyr Pharma Inc.

$6.18-6.79%10

WINTWindtree Therapeutics Inc.

$0.00+0.00%10

ZIVOZivo Bioscience Inc.

$8.00+10.34%0

PALIPalisade Bio Inc.

$1.25+1.63%20

CRDFCardiff Oncology Inc.

$0.87+1.03%36

Spot a number that looks wrong? Check it in AIM's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing AIM

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.